Indeed, Køllgaard et al. proposed that the enzymatic activity of IDO2 could influence the systemic adaptive immune response and, therefore, IDO2 expression in the tumor target cells could suppress the cytotoxic T-cell responses and vanish the immune reactivity against the potential cancer antigen IDO2 [79]. This evidence concerns the gene IDO2 and neoplasm.